header-logo header-logo

Home Login E-newsletter About us
13 November 2015
Issue: 7676 / Categories: Case law , Law digest , In Court
printer mail-detail

Patent

© Copyright LexisNexis 2026. All Rights Reserved.

Merck Sharp & Dohme Ltd v Ono Pharmaceutical Co. Ltd and another; Bristol Myers Squibb Company and others v Merck & Co Inc and another [2015] EWHC 2973 (Pat), [2015] All ER (D) 07 (Nov)

The Patents Court considered a patent relating to the use of anti-PD-1 antibodies in the treatment of cancer. The court rejected a number of objections to the validity of the patent, including lack of novelty, obviousness and entitlement to the first priority date.

If you are not a subscriber, subscribe now to read this content
If you are already a subscriber sign in
...or Register for two weeks' free access to subscriber content

MOVERS & SHAKERS

Read All
Sponsored by
Zylpha LogoClick to know more
Clarke Willmott—Anita Rasaratnam

Clarke Willmott—Anita Rasaratnam

Clarke Willmott strengthens social housing development offering with senior London appointment

Trowers & Hamlins—David Meecham

Trowers & Hamlins—David Meecham

Trowers strengthens Birmingham real estate team with partner hire

Blake Morgan—Jennifer Ray & Louise Culleton

Blake Morgan—Jennifer Ray & Louise Culleton

Blake Morgan expands private client and regulatory teams with new legal directors

NEWS
Read All
Fresh hope for jury trials?
A mood of cautious optimism has enveloped the criminal law sector following indications the Prime Minister may abandon planned jury reforms
Check out the NLJ Directory
Helping to source the services and providers you need
NLJ this week: Security denied
The Senior Courts Costs Office has clarified that judges conducting detailed assessment proceedings cannot order security for costs—a ruling that may leave successful parties exposed to further litigation expense
NLJ this week: Costs sting after a courtroom gamble
Rejecting a generous settlement can prove an expensive mistake, as two recent high-profile cases demonstrate
NLJ this week: Silence carries a price
The Financial Conduct Authority (FCA) continues to show that failing to disclose regulatory issues can attract harsher consequences than the original misconduct itself
Copyright © 2026 LexisNexis
back-to-top-scroll